Martin Steinau1, Elizabeth R Unger, Brenda Y Hernandez, Marc T Goodman, Glenn Copeland, Claudia Hopenhayn, Wendy Cozen, Maria S Saber, Youjie Huang, Edward S Peters, Charles F Lynch, Edward J Wilkinson, Mangalathu S Rajeevan, Christopher Lyu, Mona Saraiya. 1. 1Chronic Viral Diseases Branch, Centers for Disease Control and Prevention, Atlanta GA; 2University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI; 3Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA; 4Michigan Cancer Surveillance Program, Michigan Department of Community Health, Lansing, MI; 5Department of Epidemiology, University of Kentucky, Lexington, KY; 6Los Angeles Cancer Registry, Los Angeles, CA; 7Florida Department of Health, Tallahassee, FL; 8Louisiana State University Health Sciences Center, School of Public Health, New Orleans, LA; 9Department of Epidemiology, University of Iowa, Iowa City, IA; 10College of Medicine, University of Florida, Gainesville, FL; 11Battelle Memorial Institute, Durham, NC; and 12Epidemiology and Applied Research Branch, Centers for Disease Control and Prevention, Atlanta GA.
Abstract
OBJECTIVE: This study aimed to conduct a representative survey of human papillomavirus (HPV) prevalence and its genotype distribution in invasive anal cancer specimens in the United States. MATERIALS AND METHODS: Population-based archival anal cancer specimens were identified from Florida, Kentucky, Louisiana, and Michigan cancer registries and Surveillance, Epidemiology, and End Results (SEER) tissue repositories in Hawaii, Iowa, and Los Angeles. Sections from 1 representative block per case were used for DNA extraction. All extracts were assayed first by linear array and retested with INNO-LiPA if inadequate or HPV negative. RESULTS: Among 146 unique invasive anal cancer cases, 93 (63.7%) were from women, and 53 (36.3%) were from men. Human papillomavirus (any type) was detected in 133 cases (91.1%) and 129 (88.4%) contained at least 1 high risk-type, most (80.1%) as a single genotype. Human papillomavirus type 16 had the highest prevalence (113 cases, 77.4%); HPV types 6, 11, 18, and 33 were also found multiple times. Among HPV-16-positive cases, 37% were identified as prototype variant Ep, and 63% were nonprototypes: 33% Em, 12% E-G131G, 5% Af1, 4% AA/NA-1, 3% E-C109G, 3% E-G131T, 2% As, and 1% Af2. No significant differences in the distributions of HPV (any), high-risk types, or HPV-16/18 were seen between sex, race, or age group. CONCLUSIONS: The establishment of prevaccine HPV prevalence in the United States is critical to the surveillance of vaccine efficacy. Almost 80% of anal cancers were positive for the vaccine types HPV-16 or HPV-18, and in 70%, these were the only types detected, suggesting that a high proportion might be preventable by current vaccines.
OBJECTIVE: This study aimed to conduct a representative survey of human papillomavirus (HPV) prevalence and its genotype distribution in invasive anal cancer specimens in the United States. MATERIALS AND METHODS: Population-based archival anal cancer specimens were identified from Florida, Kentucky, Louisiana, and Michigan cancer registries and Surveillance, Epidemiology, and End Results (SEER) tissue repositories in Hawaii, Iowa, and Los Angeles. Sections from 1 representative block per case were used for DNA extraction. All extracts were assayed first by linear array and retested with INNO-LiPA if inadequate or HPV negative. RESULTS: Among 146 unique invasive anal cancer cases, 93 (63.7%) were from women, and 53 (36.3%) were from men. Human papillomavirus (any type) was detected in 133 cases (91.1%) and 129 (88.4%) contained at least 1 high risk-type, most (80.1%) as a single genotype. Human papillomavirus type 16 had the highest prevalence (113 cases, 77.4%); HPV types 6, 11, 18, and 33 were also found multiple times. Among HPV-16-positive cases, 37% were identified as prototype variant Ep, and 63% were nonprototypes: 33% Em, 12% E-G131G, 5% Af1, 4% AA/NA-1, 3% E-C109G, 3% E-G131T, 2% As, and 1% Af2. No significant differences in the distributions of HPV (any), high-risk types, or HPV-16/18 were seen between sex, race, or age group. CONCLUSIONS: The establishment of prevaccine HPV prevalence in the United States is critical to the surveillance of vaccine efficacy. Almost 80% of anal cancers were positive for the vaccine types HPV-16 or HPV-18, and in 70%, these were the only types detected, suggesting that a high proportion might be preventable by current vaccines.
Authors: J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz Journal: J Pathol Date: 1999-09 Impact factor: 7.996
Authors: David C Swan; Mangalathu Rajeevan; Guillermo Tortolero-Luna; Michele Follen; Ruth Ann Tucker; Elizabeth R Unger Journal: Gynecol Oncol Date: 2005-03 Impact factor: 5.482
Authors: David C Swan; Josef R Limor; Kara L Duncan; Mangalathu S Rajeevan; Elizabeth R Unger Journal: J Virol Methods Date: 2006-06-19 Impact factor: 2.014
Authors: L F Xi; C W Critchlow; C M Wheeler; L A Koutsky; D A Galloway; J Kuypers; J P Hughes; S E Hawes; C Surawicz; G Goldbaum; K K Holmes; N B Kiviat Journal: Cancer Res Date: 1998-09-01 Impact factor: 12.701
Authors: Joel M Palefsky; Anna R Giuliano; Stephen Goldstone; Edson D Moreira; Carlos Aranda; Heiko Jessen; Richard Hillman; Daron Ferris; Francois Coutlee; Mark H Stoler; J Brooke Marshall; David Radley; Scott Vuocolo; Richard M Haupt; Dalya Guris; Elizabeth I O Garner Journal: N Engl J Med Date: 2011-10-27 Impact factor: 91.245
Authors: Djenaba A Joseph; Jacqueline W Miller; Xiaocheng Wu; Vivien W Chen; Cyllene R Morris; Marc T Goodman; Jose M Villalon-Gomez; Melanie A Williams; Rosemary D Cress Journal: Cancer Date: 2008-11-15 Impact factor: 6.860
Authors: Hugo De Vuyst; Gary M Clifford; Maria Claudia Nascimento; Margaret M Madeleine; Silvia Franceschi Journal: Int J Cancer Date: 2009-04-01 Impact factor: 7.396
Authors: James L Klosky; Brianne Favaro; Kelly R Peck; Jessica L Simmons; Kathryn M Russell; Daniel M Green; Melissa M Hudson Journal: J Cancer Surviv Date: 2015-11-16 Impact factor: 4.442
Authors: Erin Isaacson Wechsler; Sharof Tugizov; Rossana Herrera; Maria Da Costa; Joel M Palefsky Journal: J Gen Virol Date: 2018-04-06 Impact factor: 3.891
Authors: Jacqueline Mix; Mona Saraiya; Charles F Lynch; Trevor D Thompson; April Greek; Thomas C Tucker; Edward S Peters; Troy D Querec; Elizabeth R Unger Journal: J Registry Manag Date: 2019
Authors: Mona Saraiya; Elizabeth R Unger; Trevor D Thompson; Charles F Lynch; Brenda Y Hernandez; Christopher W Lyu; Martin Steinau; Meg Watson; Edward J Wilkinson; Claudia Hopenhayn; Glenn Copeland; Wendy Cozen; Edward S Peters; Youjie Huang; Maria Sibug Saber; Sean Altekruse; Marc T Goodman Journal: J Natl Cancer Inst Date: 2015-04-29 Impact factor: 13.506
Authors: Laia Alemany; Maëlle Saunier; Isabel Alvarado-Cabrero; Beatriz Quirós; Jorge Salmeron; Hai-Rim Shin; Edyta C Pirog; Núria Guimerà; Gustavo Hernandez-Suarez; Ana Felix; Omar Clavero; Belen Lloveras; Elena Kasamatsu; Marc T Goodman; Brenda Y Hernandez; Jan Laco; Leopoldo Tinoco; Daan T Geraets; Charles F Lynch; Vaclav Mandys; Mario Poljak; Robert Jach; Josep Verge; Christine Clavel; Cathy Ndiaye; JoEllen Klaustermeier; Antonio Cubilla; Xavier Castellsagué; Ignacio G Bravo; Michael Pawlita; William G Quint; Nubia Muñoz; Francesc X Bosch; Silvia de Sanjosé Journal: Int J Cancer Date: 2014-05-30 Impact factor: 7.396
Authors: Elaine W Flagg; S Deblina Datta; Mona Saraiya; Elizabeth R Unger; Edward Peters; Lauren Cole; Vivien W Chen; Thomas Tucker; Mary Jane Byrne; Glenn Copeland; Won Silva; Meg Watson; Hillard Weinstock Journal: Cancer Causes Control Date: 2014-02-28 Impact factor: 2.506